Elekta presents Gamma Knife data as Elekta stock trades at EUR 4.93

Published on 10/15/2026 at 13:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Elekta presents Gamma Knife data for up to 50 brain metastases. Elekta stock costs EUR 4.93 on October 15, 2026 versus SEK 55.10 in Stockholm.

Clinical data and margin recovery

Elekta presented phase 2 Gamma Knife data for patients with up to 50 brain metastases on September 29, 2026.
First-quarter fiscal 2026/27 revenue fell to SEK 3.54 billion while adjusted gross margin reached 42.60 percent.
Elekta stock trades at EUR 4.93 at 1:41 p.m. CEST at Lang & Schwarz on October 15, 2026.
Elekta's next quarterly report is scheduled for November 25, 2026.

Modernes gläsernes Forschungsgebäude mit Glasfassade in architektonischem 3D-Render — Architektonisches 3D-Render eines modernen Forschungsgebäudes repräsentiert die Innovationskraft von Elekta AB SE0000163628 in der Medizintechnik, Illustration mit AI erstellt.

Elekta (SE0000163628) was trading at EUR 4.93 at Lang & Schwarz on October 15, 2026 at 1:41 p.m. CEST. The medical technology company had presented new phase 2 Gamma Knife data on September 29, 2026, covering patients with up to 50 brain metastases, according to Affarsvarlden.

Three events reshape the story

On August 27, 2026, Elekta reported first-quarter fiscal 2026/27 revenue of SEK 3.54 billion, down 3.00 percent year over year. Adjusted gross margin rose to 42.60 percent from 37.00 percent, while adjusted EBIT increased 68.00 percent to SEK 395.00 million, according to StockSentinel.

On September 28, 2026, Elekta highlighted an ASTRO study of 123 patients treated with Unity MR-guided adaptive radiotherapy. The study reported overall survival of 37.40 percent at two years and 26.30 percent at three years, according to FinanzNachrichten.

On September 29, 2026, the Gamma Knife update extended the clinical narrative from Unity to radiosurgery. For investors, the commercial question is whether clinical evidence can support adoption while the company works through weaker solutions revenue and stronger service growth.

What will margins require?

Management's fiscal 2026/27 outlook calls for constant-currency sales growth of 2.00 percent to 4.00 percent and an adjusted EBIT margin of 12.50 percent to 13.50 percent. Elekta also reported more than SEK 500 million in annualized savings, but the first-quarter revenue decline shows that cost control must be matched by renewed equipment demand.

On Nasdaq Stockholm, the share was last at SEK 55.10 on October 15, 2026 at 1:47 p.m. CEST while the market was open. The same quote showed a 52-week range of SEK 41.86 to SEK 66.70 and market capitalization of SEK 20.2 billion.

When are the next reports due?

Elekta lists November 25, 2026 as the date for its second-quarter report and February 25, 2027 for its third-quarter report. The November release will test whether the improved adjusted margin can persist without relying on the one-time tariff refund included in first-quarter gross margin.

Stock price and operating test

The near-term picture combines a dated clinical catalyst with a demanding execution test. Elekta must convert its Gamma Knife, Unity and adaptive-radiotherapy portfolio into orders while protecting the margin gains already visible in fiscal 2026/27.

Elekta stock was trading at EUR 4.93 at Lang & Schwarz on October 15, 2026 at 1:41 p.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Elekta stock.